Literature DB >> 19017576

Catatonic psychosis related to forced normalization in a girl with Dravet's syndrome.

Giuseppe Gobbi1, Simona Giovannini, Antonella Boni, Paola Visconti, Massimiliano Beghi, Cesare Maria Cornaggia.   

Abstract

It has been reported that the clinical presentation of forced normalization can vary from paranoid hallucinatory states to anxiety and conversion phenomena, and that it may occur in both generalised and focal epilepsies. On the basis of the evaluation of a video recording, we found that forced normalization was concomitant with catatonic psychosis in a patient with epilepsy, intellectual disability and pervasive developmental disorder. Catatonic psychosis accompanying forced normalization has not been previously reported. As the psychotic symptoms and quality of life worsen seizure control improves, we believe it may be better for the patient to tolerate some seizures, thus preserving their capacity to interact socially.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017576     DOI: 10.1684/epd.2008.0229

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  4 in total

1.  Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.

Authors:  Tristan T Sands; Shahryar Rahdari; Michael S Oldham; Eduardo Caminha Nunes; Nicole Tilton; Maria Roberta Cilio
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

2.  Development of forced normalisation psychosis with ethosuximide.

Authors:  Sean Apap Mangion; Fergus Rugg-Gunn
Journal:  BMJ Case Rep       Date:  2017-12-07

3.  FORCED NORMALIZATION: Epilepsy and Psychosis Interaction.

Authors:  Muruga A Loganathan; Manasa Enja; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2015 May-Jun

4.  Psychoses of Epilepsy in Pregnancy: A Case Report.

Authors:  Mario Fahed; Seethalakshmi Ramanathan
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.